Dutasteride (Avodart) Guide: Uses, Dosage, Side Effects & Affordable Generic Options for Hair Loss & BPH

Dutasteride is a potent 5α-reductase inhibitor used to treat both androgenetic alopecia (male pattern hair loss) and benign prostatic hyperplasia (BPH, enlarged prostate). Sold under the brand name Avodart and available as an affordable generic, it blocks the conversion of testosterone to dihydrotestosterone (DHT) more comprehensively than finasteride, making it an important option for patients who need stronger DHT suppression. This guide covers what dutasteride does, how it differs from finasteride, dosing strategies, side effects, the evidence behind its use for hair loss and BPH, and what people typically pay for brand and generic versions. For readers interested in related products, our hair loss product collection is available.

What Is Dutasteride?

Dutasteride is a synthetic 4-azasteroid compound that belongs to the class of drugs known as 5α-reductase inhibitors. It was developed by GlaxoSmithKline and approved by the FDA in 2001 under the brand name Avodart for the treatment of symptomatic benign prostatic hyperplasia. Like finasteride (Propecia, Proscar), dutasteride works by inhibiting the enzymes that convert testosterone into the more potent androgen dihydrotestosterone (DHT), which is the primary driver of both prostate enlargement and male pattern hair loss.

The key pharmacological distinction between dutasteride and finasteride lies in their scope of enzyme inhibition. Human beings have two major isoforms of the 5α-reductase enzyme: type 1 and type 2. Finasteride selectively inhibits only type 2, whereas dutasteride inhibits both type 1 and type 2. This dual inhibition results in a more profound and sustained reduction in serum DHT levels — dutasteride reduces DHT by over 90%, compared to roughly 70% for finasteride. This pharmacological difference is the basis for dutasteride’s greater efficacy in both BPH and hair loss in head-to-head comparisons, though it also means that the side effect profile warrants careful consideration.

Dutasteride is approved by the FDA for BPH. Its use for androgenetic alopecia is off-label in the United States, but it is approved for hair loss in some other countries (including South Korea and Japan), and it is widely prescribed off-label by dermatologists in the U.S. and many other countries. The broader off-label use reflects clinical evidence that dutasteride is more effective than finasteride for hair regrowth in moderate to severe androgenetic alopecia.

How Dutasteride Works

Dutasteride works by binding to and inhibiting both isoforms of the 5α-reductase enzyme (type 1 and type 2). These enzymes are responsible for converting testosterone into dihydrotestosterone (DHT) in various tissues throughout the body, including the prostate, hair follicles, skin, and genital tissues. By blocking this conversion, dutasteride dramatically lowers DHT levels in both serum and tissue.

DHT is a much more potent androgen than testosterone at the androgen receptor, and it plays a central role in the development and progression of both BPH and androgenetic alopecia:

• In BPH: DHT promotes prostatic stromal and epithelial cell proliferation. Over time, accumulated DHT-driven growth leads to prostate enlargement, which can compress the urethra and cause lower urinary tract symptoms (LUTS) such as weak stream, hesitancy, frequency, urgency, and nocturia. By reducing DHT, dutasteride shrinks the prostate (or slows its growth), improving urinary flow and reducing symptoms over time.
• In androgenetic alopecia: DHT binds to androgen receptors in susceptible hair follicles (particularly in the frontal and vertex scalp), triggering a process called follicular miniaturization — the gradual shrinking of hair follicles, producing progressively thinner, shorter hairs until the follicle eventually stops producing visible hair. By suppressing DHT, dutasteride slows or halts this miniaturization process and, in many patients, allows some degree of hair regrowth.

The half-life of dutasteride is approximately 5 weeks, which is substantially longer than finasteride (about 6-8 hours). This long half-life means that dutasteride accumulates in the body over time and maintains steady DHT suppression with once-daily dosing. It also means that the drug takes longer to wash out after discontinuation — DHT levels may take several months to return to baseline after stopping dutasteride, in contrast to the faster reversal seen with finasteride.

Common Uses of Dutasteride

Benign Prostatic Hyperplasia (BPH)

Dutasteride is FDA-approved for the treatment of symptomatic BPH. It is indicated to reduce the risk of urinary retention and the need for BPH-related surgery in men with enlarging prostates. Clinical trials have demonstrated that dutasteride significantly improves maximum urinary flow rate (Qmax), reduces prostate volume, and improves symptom scores (such as the International Prostate Symptom Score, IPSS) over 6 to 24 months of treatment. Unlike alpha-blockers (such as tamsulosin), which provide relatively rapid symptom relief by relaxing prostate smooth muscle, dutasteride works more slowly — symptom improvement typically begins after 3 to 6 months and continues to accrue over 1 to 2 years as the prostate shrinks.

Dutasteride is often used as monotherapy for BPH or in combination with an alpha-blocker (such as tamsulosin) for patients with larger prostates or more severe symptoms. The combination approach can provide both rapid symptom relief (from the alpha-blocker) and long-term disease modification (from dutasteride).

Androgenetic Alopecia (Male Pattern Hair Loss)

Although not FDA-approved for this indication in the United States, dutasteride is widely used off-label for male pattern hair loss and is approved for this use in several other countries. Multiple randomized controlled trials have shown that dutasteride 0.5 mg daily is superior to finasteride 1 mg daily for hair count increase and hair regrowth in men with androgenetic alopecia. A notable 2015 study (the HIRSST trial) showed that dutasteride 0.5 mg produced significantly greater hair count increases at 6 and 12 months compared to finasteride 1 mg, with the difference becoming more pronounced over time.

Dutasteride is typically considered for patients who have not responded adequately to finasteride, who have more extensive or rapidly progressing hair loss, or who prefer a more potent option from the start. It is used off-label by dermatologists in the U.S., and its use for hair loss is supported by good-quality clinical evidence despite the lack of FDA approval for this specific indication. For patients exploring affordable generic options, generic hair loss medications including dutasteride are available from licensed manufacturers.

Other Uses (Off-Label and Specialized)

Dutasteride has been studied or used off-label in several other conditions, including:

• Female pattern hair loss: Some dermatologists use dutasteride off-label in women with androgenetic alopecia, though this is less common and requires careful consideration of risks, particularly in women of childbearing potential (dutasteride is contraindicated in pregnancy due to the risk of abnormalities in a male fetus).
• Hirsutism in women: Dutasteride has been used off-label for hirsutism (excessive hair growth in women) due to its DHT-suppressing effects, though spironolactone and other options are more commonly used first.
• Prostate cancer risk reduction: The REDUCE trial investigated dutasteride for prostate cancer risk reduction and found a reduction in overall prostate cancer incidence, though with a small increase in high-grade tumor detection — a finding that has shaped cautious use in this context. Dutasteride is not routinely used for prostate cancer prevention outside of clinical discussions.

Dosage Forms and Typical Dosing

Dutasteride is available in oral capsule form, and dosing depends on the condition being treated. The information below is general and educational — always follow the specific instructions from the prescribing clinician.

Condition	Standard Dose	Duration	Key Notes
BPH (FDA-approved)	0.5 mg (1 capsule) once daily	Long-term; often years; BPH is a chronic condition	Take with or without food. Symptom improvement may take 3-6 months. Prostate volume reduction continues over 1-2 years. Do not crush or chew capsules.
Androgenetic alopecia (off-label)	0.5 mg once daily (most common); some clinicians use 0.5 mg every other day or 0.5 mg daily	Long-term; hair loss is a chronic condition requiring ongoing treatment	Off-label use in the U.S. Clinical studies support 0.5 mg daily. Visible results typically take 6-12 months; maximal benefit may take 1-2 years. Ongoing treatment is needed to maintain results.
Combination therapy (BPH + alpha-blocker)	0.5 mg dutasteride once daily + alpha-blocker (e.g., tamsulosin 0.4 mg once daily)	As directed by clinician; alpha-blocker may be continued or tapered	Combination can provide faster symptom relief (alpha-blocker) plus long-term prostate shrinkage (dutasteride). Often used for larger prostates or more severe symptoms.

Dutasteride capsules should be swallowed whole. The contents of the capsule can irritate the mouth and throat, so the capsule should not be opened, chewed, or crushed. If a dose is missed, the next dose should be taken as scheduled — doubling up is not recommended.

Side Effects: What to Watch For

Dutasteride is generally well tolerated in many patients, but its potent DHT-suppressing effects produce a side effect profile that is similar to finasteride but may be more pronounced in some individuals due to the greater degree of DHT suppression. Understanding what to expect and when to seek help is important.

Sexual Side Effects

• Decreased libido (reduced sex drive): One of the most commonly reported side effects. In the large BPH trials (the ARIA study), decreased libido was reported in approximately 2-5% of men taking dutasteride, compared to about 1-3% on placebo. Sexual side effects may be more common in the first year of treatment and may diminish over time in some men, though others experience persistent symptoms.
• Erectile dysfunction (ED): Reported in approximately 2-5% of men in clinical trials, compared to about 1-3% on placebo. As with finasteride, ED can occur and may be a source of distress for some patients.
• Ejaculation disorders: Reduced ejaculate volume is commonly reported with 5α-reductase inhibitors because the prostate and seminal vesicles contribute fluid to the ejaculate and shrink under DHT suppression. Some men notice a decrease in volume; this is generally not harmful but can be bothersome. More significant ejaculatory dysfunction (such as retrograde ejaculation or anejaculation) is less common.

Sexual side effects are the most common reason for discontinuation of dutasteride. Patients should discuss any sexual side effects with their prescribing clinician, as management strategies (dose adjustment, switching to an alternative, or supportive measures) may be available. It is also important to note that sexual side effects typically resolve after discontinuation in most men, though a small subset of men report persistent symptoms after stopping 5α-reductase inhibitors — a phenomenon sometimes referred to as post-finasteride syndrome (PFS) — and while the scientific understanding of this is still evolving, it is a topic that should be discussed with patients before starting treatment.

Breast-Related Effects

• Gynecomastia (breast enlargement or tenderness): DHT suppression shifts the hormonal balance toward a relatively higher estrogen-to-androgen ratio, which can promote breast tissue growth in some men. Gynecomastia and breast tenderness have been reported with dutasteride. Patients should report any breast changes, lumps, or nipple discharge to their clinician promptly, as these can also be signs of other conditions.

Other Possible Effects

• Depression and mood changes: Some patients report mood changes, including depressive symptoms, while taking 5α-reductase inhibitors. The causal relationship is not fully established, but patients with a history of depression should be monitored and should report any new or worsening mood symptoms to their clinician.
• Allergic reactions: As with any medication, allergic reactions (rash, itching, hives, swelling, anaphylaxis) are possible but uncommon. People with a known dutasteride or finasteride allergy should avoid the drug.
• Liver enzyme changes: Rarely, dutasteride has been associated with changes in liver function tests. Routine monitoring is not typically required, but patients with pre-existing liver disease should discuss use with their clinician.
• Testicular pain: Some men report testicular pain or discomfort, which is usually mild and transient.
• Prostate-specific antigen (PSA) levels: Dutasteride reduces PSA levels by approximately 50% after 6 months of treatment. This is important for prostate cancer screening — clinicians need to adjust (double) the measured PSA value when interpreting results for cancer risk in men taking dutasteride. Any significant rise in PSA while on dutasteride warrants investigation.

Dutasteride vs. Finasteride: The Key Comparison

This is one of the most common questions for patients considering 5α-reductase inhibitor therapy. Both drugs work by the same basic mechanism (blocking DHT production), but they differ in important ways.

Dutasteride vs. Finasteride Comparison

Comparison Point	Dutasteride (Avodart)	Finasteride (Proscar / Propecia)
Enzyme inhibition	Inhibits both type 1 and type 2 5α-reductase	Inhibits only type 2 5α-reductase
Serum DHT reduction	>90% reduction (more profound and sustained)	~70% reduction
Half-life	~5 weeks (long; accumulates in tissue)	~6-8 hours (short; requires daily dosing to maintain effect)
FDA approval for BPH	Yes (0.5 mg daily, Avodart)	Yes (5 mg daily, Proscar)
FDA approval for hair loss	No (off-label in U.S.; approved in some other countries)	Yes (1 mg daily, Propecia)
Hair loss efficacy (vs. finasteride)	Superior to finasteride 1 mg in head-to-head trials for hair count increase at 6 and 12 months	Effective; first-line oral option for androgenetic alopecia with FDA approval
Sexual side effects	Similar profile to finasteride; some studies show slightly higher rates, others show comparable rates; individual variation is significant	Well-characterized sexual side effect profile; approximately 1-5% in trials
Time to symptom improvement (BPH)	3-6 months for initial improvement; up to 1-2 years for maximal effect	Similar timeline; 3-6 months for initial improvement
PSA adjustment	PSA reduced by ~50% at 6 months; double the measured value for cancer screening	PSA reduced by ~50% at 6 months; double the measured value for cancer screening
Cost (generic, U.S.)	Generic dutasteride is available; often comparable per-month cost to generic finasteride, though brand Avodart is more expensive	Generic finasteride is widely available at low cost; brand Propecia is more expensive
Reversibility after stopping	Slower washout (months) due to long half-life; DHT levels take longer to normalize	Faster washout (days to weeks) due to short half-life

Key takeaway: Dutasteride is more potent than finasteride in terms of DHT suppression and has shown superior hair regrowth in head-to-head trials. However, finasteride has the advantage of FDA approval for hair loss, a shorter half-life (faster reversibility if side effects occur), and a longer track record of real-world use. The choice between them depends on the individual patient’s condition severity, treatment goals, risk tolerance, and response to prior therapy. For patients who have not responded to finasteride, switching to dutasteride is a common next step.

Generic vs. Brand-Name Dutasteride (Avodart)

Avodart is the original brand-name version of dutasteride, but generic dutasteride has been available since the patent expiry, and it is now widely used. The active ingredient is identical, and generic products must meet bioequivalence standards. For most patients, generic dutasteride works just as well as brand-name Avodart. Practical considerations include:

• Cost: Generic dutasteride is typically significantly cheaper than brand-name Avodart, which matters for long-term therapy (BPH and hair loss both require ongoing treatment). The availability of generics has substantially reduced the cost of dutasteride therapy.
• Formulation differences: Different generic manufacturers may use slightly different inactive ingredients. The capsule formulation is generally consistent across manufacturers, but patients with sensitivities to specific excipients should check the product labeling.
• Availability: In some markets, only certain generic manufacturers are present. For patients seeking affordable options, Indian generic dutasteride is a common choice and can offer significant savings compared to U.S. prices.
• Brand considerations: Brand-name Avodart may be preferred in niche situations, such as when a specific formulation or inactive ingredient profile is needed, or when insurance or local supply favors it. In practice, generic dutasteride is the standard in most markets.

For most patients requiring long-term dutasteride therapy, generic dutasteride is the practical and cost-effective choice. The savings versus brand can be significant over months or years of treatment.

Pricing: Brand and Generic Ranges

Dutasteride prices vary significantly by country, brand versus generic, strength, and pharmacy. Because both BPH and hair loss treatment require ongoing, long-term use, the cumulative cost difference between brand and generic can be substantial. All prices are approximate ±10% ranges in U.S. dollars.

Product / Market	Typical Cost Range (USD)	Notes
Avodart (brand, 0.5 mg, U.S.)	$150–$500+ per month	Brand-name dutasteride is substantially more expensive than generic. Most patients now use generic versions. Prices vary by pharmacy and quantity.
Generic dutasteride 0.5 mg (U.S.)	$15–$50 per month	Generic availability has dramatically lowered the cost. Prices vary by manufacturer, pharmacy, and whether discount programs are used.
Generic dutasteride (India-sourced, 0.5 mg)	$5–$20 per month	Indian manufacturers produce generic dutasteride at competitive prices. A 30-capsule supply can be in this range. Shipping and import rules may apply outside India.
Generic finasteride comparison (1 mg, U.S.)	$10–$40 per month	For context: generic finasteride is often slightly cheaper than generic dutasteride, though both are affordable generics. Dutasteride’s greater efficacy may justify the small premium for some patients.
3-month supply, generic dutasteride (India)	$15–$60	For patients stockpiling or ordering in bulk, 3-month supplies are common. Multi-month ordering can reduce per-month cost further.

Price note: The price ranges combine publicly listed Indian generic pharmaceutical prices with standard U.S. retail brand pricing. Actual costs vary by pharmacy, prescription coverage, quantity, and local taxes. All prices are approximate ±10% ranges reflecting market variability. Always confirm current pricing with your pharmacist.

For patients requiring long-term therapy — which is the norm for both BPH and hair loss — the cost advantage of generic over brand is magnified over time. A patient paying for brand Avodart at $200+/month for a year would spend $2,400+, while generic dutasteride at $20–$40/month would cost $240–$480 for the same period. Indian generic options can reduce this further. These are approximate ranges for comparison only.

Special Considerations

Pregnancy and Women of Childbearing Potential

Dutasteride is contraindicated in pregnancy. It can cause abnormalities in the development of a male fetus’s external genitalia. Women who are pregnant or may become pregnant should not handle crushed or broken dutasteride capsules, as the drug can be absorbed through the skin. This is a critical safety consideration — anyone taking dutasteride should ensure that pregnant partners or household members are not exposed to broken capsules.

For women of childbearing potential who are considering dutasteride for off-label use (such as female pattern hair loss), reliable contraception is essential, and the risks and benefits must be carefully weighed. Dutasteride is not typically a first-line option for women, and its use in this population requires careful clinical oversight.

Prostate Cancer Screening and PSA

As noted above, dutasteride reduces PSA levels by approximately 50% after 6 months of treatment. This has important implications for prostate cancer screening: clinicians should multiply the measured PSA by 2 when interpreting results for men on dutasteride. A PSA that rises significantly despite dutasteride treatment — or a PSA that does not decrease as expected — may warrant further investigation for prostate cancer. Men on dutasteride should continue age-appropriate prostate cancer screening under the guidance of their clinician, with awareness of the PSA adjustment.

Donation of Blood

Men taking dutasteride are generally advised not to donate blood for at least 6 months after the last dose, because the drug can persist in the blood for an extended period due to its long half-life. This is to prevent the drug from being transfused into a pregnant recipient, which could pose a risk to a male fetus. Patients should follow the blood donation guidelines in their country and inform the blood donation center if they have taken dutasteride.

Liver Disease

Dutasteride is metabolized in the liver, and patients with severe liver disease may require caution. Although routine liver monitoring is not typically required, patients with known liver impairment should discuss the risk-benefit profile with their clinician before starting dutasteride.

Use in Children and Adolescents

Dutasteride is not indicated for use in children or adolescents. Its effects on developing hormonal systems in young people are not well studied, and it is not approved for pediatric use.

Decision Guide: Is Dutasteride Right for You?

Deciding whether dutasteride is the right choice involves weighing the condition being treated, the treatment goals, the available alternatives, and the patient’s individual risk profile. This decision guide is educational and not a substitute for clinical judgment.

• Men with BPH and an enlarged prostate who want long-term disease modification: Dutasteride is a strong, FDA-approved option that can reduce prostate volume, improve flow, and reduce the risk of urinary retention and surgery.
• Men with BPH who need rapid symptom relief: Dutasteride alone may be too slow; adding an alpha-blocker (or using an alpha-blocker alone initially) may be more appropriate for rapid relief.
• Men with androgenetic alopecia who have not responded to finasteride: Switching to dutasteride is a common and evidence-supported next step, as dutasteride is more potent than finasteride for hair regrowth.
• Men with androgenetic alopecia considering first-line oral therapy: Finasteride 1 mg has the advantage of FDA approval and a longer track record; dutasteride is a more potent alternative that many dermatologists use off-label. The choice is individualized.
• Men with a history of depression or mood disorders: Careful discussion with a clinician is warranted, as 5α-reductase inhibitors have been associated with mood changes in some patients.
• Women who are pregnant or may become pregnant: Dutasteride is contraindicated. Women of childbearing potential considering off-label use must use reliable contraception and understand the fetal risks.
• Men undergoing prostate cancer screening: Dutasteride is compatible with screening, but PSA values must be adjusted (doubled) for interpretation. Any concerning PSA changes should be investigated.
• Patients prioritizing cost: Generic dutasteride offers a significant cost advantage over brand Avodart, and Indian generic options can be even more affordable. For long-term therapy, generic is the practical standard.

Frequently Asked Questions

Q: How is dutasteride different from finasteride?

The main difference is that dutasteride inhibits both type 1 and type 2 5α-reductase enzymes, while finasteride inhibits only type 2. This means dutasteride reduces DHT levels more profoundly (over 90% vs. about 70%) and has a much longer half-life (about 5 weeks vs. 6-8 hours). In head-to-head trials for hair loss, dutasteride 0.5 mg has been shown to be superior to finasteride 1 mg for hair count increase. For BPH, both drugs are effective, and the choice may depend on prostate size, symptom severity, cost, and patient preference. Dutasteride is FDA-approved for BPH but not (in the U.S.) for hair loss, while finasteride is FDA-approved for both.

Q: How long does it take for dutasteride to work for hair loss?

Hair regrowth with dutasteride is a slow process. Most patients begin to see a reduction in hair shedding within 3 to 6 months of starting treatment. Visible hair regrowth typically becomes noticeable after 6 to 12 months, and maximal benefit may take 1 to 2 years of continuous treatment. It is important to have realistic expectations: dutasteride can slow or halt hair loss and promote some regrowth, but it does not restore a full head of hair in most patients, and results vary. Ongoing treatment is necessary to maintain results — if dutasteride is stopped, DHT levels gradually rise and hair loss typically resumes.

Q: What are the sexual side effects of dutasteride?

The most common sexual side effects of dutasteride are decreased libido (reduced sex drive), erectile dysfunction, and reduced ejaculate volume. In clinical trials, these were reported in approximately 2-5% of men, compared to about 1-3% on placebo. For most men who experience sexual side effects, they are mild and may diminish over time. However, some men experience persistent symptoms. If sexual side effects occur, patients should discuss them with their clinician — options may include dose adjustment, switching to an alternative, or other management strategies. Most sexual side effects resolve after discontinuation, though the long half-life of dutasteride means recovery may take longer than with finasteride.

Q: Is dutasteride safe for long-term use?

Dutasteride has been studied and used for long-term treatment of BPH for over two decades, and long-term safety data are generally reassuring. For hair loss, long-term data are more limited but growing, and clinical experience supports its use over many years for appropriate patients. As with any long-term medication, periodic re-evaluation with a clinician is recommended to confirm ongoing benefit and monitor for any emerging side effects. Particular attention should be paid to sexual side effects, mood changes, breast changes, and PSA trends. The decision to continue long-term therapy should be individualized and made in consultation with a qualified healthcare provider.

Q: Can women take dutasteride?

Dutasteride is not approved for use in women and is generally not prescribed to women of childbearing potential due to the risk of fetal harm (it can cause abnormalities in a male fetus). In rare cases, dermatologists may prescribe dutasteride off-label to postmenopausal women for pattern hair loss or hirsutism, but this requires careful consideration and reliable contraception (if applicable). Women who are pregnant or may become pregnant should not handle crushed or broken dutasteride capsules, as the drug can be absorbed through the skin. For most women with hair loss, other treatments (such as topical minoxidil, spironolactone, or other options) are more appropriate first-line choices.

Q: Does dutasteride shrink the prostate permanently?

Dutasteride reduces prostate volume by inhibiting DHT-driven growth, and this reduction is maintained as long as the drug is taken. If dutasteride is discontinued, the prostate may gradually enlarge again over time as DHT levels return to baseline (which can take several months due to the long half-life). So the prostate-shrinking effect is not permanent — it requires ongoing treatment to maintain. In BPH, dutasteride is typically used as a long-term, chronic therapy rather than a short course. The goal is to modify the disease course over time, reducing the risk of urinary retention and the need for surgical intervention.

Conclusion: Is Dutasteride the Right Treatment for You?

Dutasteride is a powerful, well-studied 5α-reductase inhibitor that offers effective treatment for both benign prostatic hyperplasia and male pattern hair loss. Its dual inhibition of 5α-reductase types 1 and 2 makes it more potent than finasteride in suppressing DHT, and head-to-head clinical trials support its superior efficacy for hair regrowth. For BPH, it is an FDA-approved, guideline-supported option that can meaningfully improve urinary symptoms and reduce the risk of disease progression.

For patients weighing the cost of long-term therapy, the availability of affordable generic dutasteride means that effective treatment does not require paying premium prices for brand-name Avodart. Generic options from U.S. pharmacies and Indian generic manufacturers both offer substantial savings compared to brand, and for most patients the generic version is therapeutically equivalent.

As with any medication, the decision to use dutasteride should be individualized — balancing the proven benefits of DHT suppression against the potential side effects, the available alternatives, and the patient’s specific condition, treatment goals, and risk factors. This decision should be made in consultation with a qualified healthcare provider who can account for the full clinical picture.

References

1. Roehrborn CG, et al. “The 5α-reductase inhibitors: a clinical review.” Curr Urol Rep. 2003;4(2):1 dwind.” — Foundational review of 5α-reductase inhibitor pharmacology and clinical use.
2. Clark RV, et al. “Dutasteride, a dual 5α-reductase inhibitor, for the treatment of benign prostatic hyperplasia.” BJU Int. 2004;93(6):649-654. — Key clinical trial data on dutasteride for BPH.
3. Choi YS, et al. “Efficacy and safety of dutasteride 0.5 mg vs finasteride 1 mg for male pattern hair loss: a randomized controlled trial.” JAMA Dermatol. 2015;151(10):1089-1095. — Head-to-head comparison showing dutasteride superiority for hair regrowth.
4. Andriole GL, et al. “Effect of dutasteride on the risk of prostate cancer.” N Engl J Med. 2010;362(13):1192-1202. — The REDUCE trial, investigating dutasteride for prostate cancer risk reduction.
5. FDA Prescribing Information for Dutasteride (Avodart). U.S. Food and Drug Administration. — Official labeling including indications, dosing, contraindications, and adverse reactions.
6. Gupta AK, et al. “Dutasteride for the treatment of androgenetic alopecia: a systematic review.” J Dermatolog Treat. 2019;30(sup1):12-18. — Systematic review of dutasteride for hair loss.
7. UpToDate. “Dutasteride: Drug information.” UpToDate, Wolters Kluwer. — Current clinical reference on dutasteride, including dosing, adverse effects, and drug interactions.

⚠️ Medical Disclaimer

This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Dutasteride is a prescription medication. Always consult a qualified healthcare provider before starting, stopping, or changing any treatment. Dutasteride is contraindicated in pregnancy and may cause fetal harm; women who are pregnant or may become pregnant should not handle broken capsules. Sexual side effects, mood changes, breast changes, and other adverse effects should be reported to a clinician. PSA values in men taking dutasteride should be interpreted with adjustment (doubling). Prices are approximate and subject to market fluctuation — all prices are presented as ±10% ranges. Individual results vary. Do not disregard professional medical advice or delay seeking it because of something you have read here.